Bristol, Tennessee-based King Pharmaceuticals said that it “intends to vigorously enforce the patent.” The patent extends through November 25, 2017.
Under the federal Hatch-Waxman Act of 1984, any generic manufacturer may file an abbreviated new drug application challenging the validity or infringement of a patent listed in the FDA's approved drug products with therapeutic equivalence evaluations (the Orange Book) for a reference listed drug.